Myomo, Inc. (MYO) AI Stock Analysis

Headquartered in Boston, Massachusetts, Myomo, Inc. is a wearable medical robotics company that designs, develops, and manufactures myoelectric orthotics for people with neuromuscular disorders across the United States. Founded in 2004, its flagship offering is MyoPro, a myoelectric-controlled upper limb orthosis designed to support weak or paralyzed arms and assist with daily living activities. MyoPro serves adults and adolescents affected by conditions such as stroke, brachial plexus injury, spinal cord injury, and traumatic brain injury. The company distributes its products through orthotics and prosthetics providers, rehabilitation hospitals, the Veterans Health Administration, and specialized distributor networks.

Myomo increased revenue from $13.9M in FY2021 to $19.2M in FY2023, $32.6M in FY2024, and $40.9M in FY2025, marking 25.7% revenue growth in FY2025. Gross margin contracted from 74.4% in FY2021 to 65.7% in FY2025. Operating margins also remained negative across all periods, landing at -35.2% in FY2025 as research and development expenses rose to $6.9M. Net income came in at -$10.4M in FY2021, -$6.2M in FY2024, and -$15.6M in FY2025. For the trailing twelve months ended June 30, 2026, revenue totaled $43.3M with a profit margin of -33.5%, while latest quarterly revenue expanded 21.3% year-over-year.

As of June 30, 2026, Myomo reported $13.5M in cash and short-term investments against $20.1M in total debt, resulting in net debt of $6.6M. The company finished the period with a current ratio of 2.31, shareholders' equity of $5.8M, and a debt-to-equity ratio of 3.44. In FY2025, operating cash flow was -$14.5M and capital expenditures were $1.7M, generating free cash flow of -$16.3M. Over the trailing five years, Myomo's share count increased 552.1%.

With a market capitalization of $47.5M and an enterprise value of $71.6M, Myomo trades at a price-to-sales multiple of 1.1x and an EV-to-revenue multiple of 1.7x. Its price-to-sales multiple is below the median of 4.1x for US-listed Healthcare peers, while its price-to-book ratio is 11.1x. Over the past year, the stock gained 11.1%, trailing the S&P 500's return of 16.8%. Over a five-year timeframe, Myomo fell 91.0%, while the S&P 500 returned 83.0%.

Consensus coverage shows 3 Strong Buy and 2 Buy recommendations, with no Hold, Sell, or Strong Sell ratings. The average price target is $4.64, representing a 286.7% premium over the October 16, 2026 closing price of $1.20. For the fiscal year ending December 31, 2026, analysts estimate revenue of $45.6M and an EPS of -$0.31. For the following fiscal year, 3 analysts project revenue of $51.2M, representing 12.3% growth, alongside an EPS of -$0.22. Myomo beat EPS estimates in 3 of the last 4 quarters, and its next earnings date is November 9, 2026.

This page is an AI-written research summary of Myomo, Inc. (MYO). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: MYO income statement, MYO balance sheet, MYO key metrics, MYO analyst forecast, MYO chart. See the MYO stock overview for the latest quote and news.